InterHealth Nutraceuticals has completed a multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers, confirming the safety and efficacy of Aller-7 in people with allergic rhinitis, or airborne allergies. The study, published in the International Journal of Clinical Pharmacology Research (XXIV (2/3):79-94, 2004), found that over a period of 12 weeks, 94% of patients in open label trials and 92% of patients in double-blind, placebo-controlled trials treated with Aller-7 reported an improvement in symptoms ranging from more than 40% to 100%. Complete relief from sneezing, running nose and nasal congestion in open label trials was seen in 28%, 37% and 45% of patients, respectively. No serious side effects were observed, thus demonstrating that Aller-7 is both well tolerated and efficacious in combating the symptoms of airborne allergies. Aller-7 is a patented blend of seven herbal extracts, including Phyllanthus emblica (fruit), Terminalia chebula (fruit), Terminalia bellerica (fruit), Albizia lebbeck (bark), Zingiber officinale (root), Piper longum (fruit) and Piper nigrum (fruit).